为肝细胞癌武装 GPC3 CAR-T 细胞:多少才足够,下一步是什么?
Armouring GPC3 CAR T cells for hepatocellular carcinoma: how much is enough and what comes next?
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Exploration of heterogeneity and recurrence signatures in hepatocellular carcinoma.
Exploration of heterogeneity and recurrence signatures in hepatocellular carcinoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
肝细胞癌(HCC)是全球第六大高发癌症,以高复发率和不良预后为特征。研究复发性HCC的异质性并确定关键治疗靶点,可能有助于设计有效的抗癌疗法。
在本研究中,对原发性和早期复发性HCC的单细胞RNA测序数据进行整合分析,发现复发性HCC中浸润性CD8+ T细胞以及恶性细胞比例增加,而CD4+ T细胞减少。细胞相互作用和免疫组化分析提出MIF-(CD74 + CXCR4)信号通路是恶性细胞影响肿瘤微环境中免疫细胞的关键机制。
值得注意的是,原发性恶性细胞表现出更强的分化和增殖潜能,而复发性细胞则表现出增强的上皮-间质转化和炎症,同时糖原合成和代谢相关基因表达上调。利用机器学习技术对bulk RNA-seq数据进行分析,我们开发了一种复发性肿瘤细胞相关风险评分(RTRS),该评分可独立预测总生存期和无复发生存时间,且与传统临床变量相比具有更高的准确性。通过小鼠植入模型的RT-qPCR验证了预后生物标志物和潜在治疗靶点。这项综合性研究阐明了复发性HCC的异质性,并构建了一种新型术后复发预后模型,为靶向治疗和改善患者预后开辟了道路。
Hepatocellular carcinoma (HCC), the sixth most prevalent cancer globally, is characterized by high recurrence rates and poor prognosis. Investigating the heterogeneity of relapsed HCC and identifying key therapeutic targets may facilitate the design of effective anticancer therapies.
In this study, integrative analysis of single-cell RNA sequencing data of primary and early-relapsed HCC revealed increased proportions of infiltrating CD8 + T cells along with malignant cells and a decrease in CD4 + T cells in relapsed HCC. Cellular interaction and immunohistochemical analysis proposed MIF-(CD74 + CXCR4) signaling pathway as a key mechanism by which malignant cells influence immune cells within the tumor microenvironment.
Notably, primary malignant cells showed greater differentiation and proliferation potential, whereas relapsed cells exhibited enhanced epithelial-mesenchymal transition and inflammation, along with upregulated glycogen synthesis and metabolism-related gene expression. Using machine learning techniques on bulk RNA-seq data, we developed a relapsed tumor cell-related risk score (RTRS) that independently predicts overall and recurrence-free survival time with higher accuracy compared with conventional clinical variables.
Prognostic biomarkers and potential therapeutic targets were validated via RT-qPCR using mouse implantation models. This comprehensive investigation elucidates the heterogeneity of relapsed HCC and constructs a novel postoperative recurrence prognostic model, paving the way for targeted therapies and improved patient outcomes.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。